Observational studyInternational journal of chronic obstructive pulmonary disease2025
Short-Term Outcomes of Bronchoscopic Thermal Vapor Ablation in Patients with Severe COPD: A Case Series from a Single Chinese Center.
Observational study in International journal of chronic obstructive pulmonary disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Background and Objective: Bronchoscopic Thermal Vapor Ablation (BTVA) is a novel endoscopic lung volume reduction (ELVR) technique designed to target emphysematous segments and reduce lung hyperinflation, especially in patients with heterogeneous emphysema. Although previous studies have demonstrated its efficacy in Western populations, data regarding BTVA outcomes in Asian cohorts remain limited. This study aimed to evaluate the short-term efficacy and safety of BTVA in patients with severe COPD in a real-world clinical setting. Methods: This single-center, retrospective, observational study included 8 patients with advanced COPD who underwent BTVA at the Eighth Affiliated Hospital of Sun Yat-sen University between May 2023 and December 2024. Pulmonary function (FEV Results: All patients completed the 6-month follow-up. Significant improvements in FEV Conclusion: BTVA appears to be a safe and effective minimally invasive intervention for selected patients with advanced COPD, leading to significant short-term improvements in lung function, exercise capacity, and hyperinflation. These findings support the clinical utility of BTVA in Asian populations, although larger prospective studies are needed to confirm long-term benefits and assess repeatability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.